Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study

被引：0
|
作者：
Savitz, A. [1 ]
Gopal, S. [1 ]
Xu, H. [1 ]
Zhuo, J. [2 ]
Yu, L. [2 ]
Nuamah, I. [1 ]
Wu, C. [2 ]
Hough, D. [1 ]
Mathews, M. [1 ]
Feng, Y. [2 ]
机构：
[1] Janssen Res & Dev, Titusville, NJ USA
[2] Janssen Res & Dev, Beijing, Peoples R China
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PM419
引用
收藏
页码：201 / 201
页数：1
相关论文
共 50 条
  • [11] Clinical effectiveness of paliperidone palmitate 3-monthly and 1-monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database
    Chiang, Chih-Lin
    Chinen, Madoka
    Daskiran, Mehmet
    Wakamatsu, Akihide
    Turkoz, Ibrahim
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2024, 44 (04) : 716 - 727
  • [12] Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
    Corbeil, Olivier
    Essiambre, Anne-Marie
    Bechard, Laurent
    Roy, Audrey-Anne
    Huot-Lavoie, Maxime
    Brodeur, Sebastien
    Chandrasena, Ranjith
    Theriault, Chantale
    Crocker, Candice
    Melun, Jean-Pierre
    Tibbo, Phil
    Demers, Marie-France
    Roy, Marc-Andre
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2022, 12
  • [13] Paliperidone Palmitate 3-month Versus 1-month Formulation In Patients With Schizophrenia: A Randomized, Double-blind, Noninferiority Study
    Savitz, Adam
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Ravenstijn, Paulien
    Janik, Adam
    Schotte, Alain
    Hough, David
    Fleischhacker, Wolfgang W.
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 354S - 354S
  • [14] Successful transition from 1-monthly to 3-monthly paliperidone palmitate and its associative factors in patients with schizophrenia: a population-based cohort study
    Lin, C. H.
    Lin, H. L.
    Chiang, C. L.
    Chen, Y. W.
    Wang, S. P.
    Liu, Y. F.
    Yang, Y. K.
    Tang, C. H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S117 - S118
  • [15] Clinical effectiveness of paliperidone palmitate intramuscular 3-monthly formulation in patients with schizophrenia: A case series
    Porras Segovia, A.
    Guerrero, M.
    Carrillo de Albornoz, C.
    Gutierrez-Rojas, L.
    EUROPEAN PSYCHIATRY, 2018, 48 : S533 - S533
  • [16] Prospective analysis of serum prolactin levels, clinical symptomatology and sexual functions in patients with schizophrenia switched to paliperidone palmitate 3-monthly from paliperidone palmitate 1-monthly: Preliminary findings of the first 3 months
    Karslioglu, Ersin Hatice
    Kolcu, Zeynep
    Karslioglu, Nisa Irem
    Caykoylu, Ali
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2022, 37 (03)
  • [17] SYMPTOMATIC REMISSION WITH PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA PATIENTS IN A CLINICAL PRACTICE SETTING
    Garcia-Portilla, M. P.
    Llorca, P. M.
    Maina, G.
    Bozikas, V. P.
    Devrimci-Ozguven, H.
    Kim, S. W.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    Najarian, Dean
    Pungor, K.
    SCHIZOPHRENIA BULLETIN, 2019, 45 : S295 - S296
  • [18] Paliperidone Palmitate 3-month vs 1-month Formulation in Patients with Schizophrenia: A Randomized, Double-Blind, Noninferiority Study
    Fleischhacker, W.
    Savitz, Adam
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Ravenstijn, Paulien
    Janik, Adam
    Schotte, Alain
    Hough, David
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S398 - S399
  • [19] Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
    Takahashi, Nagahide
    Takahashi, Masayoshi
    Saito, Takayuki
    Iizumi, Misuzu
    Saito, Yuki
    Shimizu, Hiroko
    Matsumura, Taka
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 1889 - 1897
  • [20] Efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia: a 13-week double-blind study
    Wakamatsu, A.
    Takahashi, N.
    Takahashi, M.
    Saito, T.
    Iizumi, M.
    Saito, Y.
    Shimizu, H.
    Matsumura, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S466 - S466
12345